| 000 | 01726 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515015128.0 | ||
| 264 | 0 | _c20060509 | |
| 008 | 200605s 0 0 eng d | ||
| 022 | _a0043-5325 | ||
| 024 | 7 |
_a10.1007/s00508-005-0505-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWorel, Nina | |
| 245 | 0 | 0 |
_aAutologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. _h[electronic resource] |
| 260 |
_bWiener klinische Wochenschrift _cFeb 2006 |
||
| 300 |
_a49-53 p. _bdigital |
||
| 500 | _aPublication Type: Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAmyloidosis _xcomplications |
| 650 | 0 | 4 |
_aChemotherapy, Adjuvant _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft Rejection _xetiology |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyeloablative Agonists _xadministration & dosage |
| 650 | 0 | 4 |
_aTransplantation, Autologous _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSchulenburg, Axel | |
| 700 | 1 | _aMitterbauer, Margit | |
| 700 | 1 | _aKeil, Felix | |
| 700 | 1 | _aRabitsch, Werner | |
| 700 | 1 | _aKalhs, Peter | |
| 700 | 1 | _aGisslinger, Heinz | |
| 700 | 1 | _aRaderer, Markus | |
| 700 | 1 | _aGeissler, Klaus | |
| 700 | 1 | _aHöcker, Paul | |
| 700 | 1 | _aZielinski, Christoph C | |
| 700 | 1 | _aOberbauer, Rainer | |
| 700 | 1 | _aGreinix, Hildegard T | |
| 773 | 0 |
_tWiener klinische Wochenschrift _gvol. 118 _gno. 1-2 _gp. 49-53 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00508-005-0505-x _zAvailable from publisher's website |
| 999 |
_c16100916 _d16100916 |
||